Detailed Coverage

Bliss GVS Pharma Faces Open Offer Triggered by Anupam Rasayan Acquisition

Anupam Rasayan India Limited's planned acquisition of 43.11% stake in Bliss GVS Pharma Limited has triggered an open offer for 26% of the company's expanded voting share capital at INR 299 per share.

Reader Takeaway: Acquisition triggers offer, but market price premium is a key investor consideration.

What Just Happened

Anupam Rasayan India Limited (the Acquirer) is set to acquire 4,58,03,024 equity shares of Bliss GVS Pharma Limited, representing 43.11% of its equity share capital. This acquisition will result in a change of control for Bliss GVS Pharma. As a consequence, the Acquirer, along with Mates Visa Consultancy Private Limited (PAC), is launching an open offer to purchase an additional 2,77,26,848 equity shares from the public shareholders. This represents 26% of the expanded voting share capital.

The offer price has been fixed at INR 299.00 per share.

Why This Matters

This event signals a significant shift in the ownership structure of Bliss GVS Pharma, potentially bringing it under the strategic umbrella of Anupam Rasayan. For existing public shareholders, the open offer presents an opportunity to exit their investment at a defined price. However, the crucial aspect for investors is the substantial difference between the offer price and the current market valuation, requiring careful consideration.

The Backstory

Anupam Rasayan India Limited, a custom synthesis and specialty chemical company, is expanding its reach. Bliss GVS Pharma Limited operates in the pharmaceutical sector. The acquisition is a strategic move by Anupam Rasayan.

What Changes Now

If the open offer is successful and Anupam Rasayan acquires the targeted shares, it will gain control of Bliss GVS Pharma. This could lead to integration of operations, strategic decisions, and potential changes in business direction. Public shareholders have the option to tender their shares at INR 299.00.

Risks to Watch

The Committee of Independent Directors (IDC) has highlighted a significant risk for public shareholders: the offer price of INR 299.00 is considerably lower than the prevailing market price. As of July 17, 2026, the market price on BSE was INR 482.50 and on NSE was INR 483.50. The IDC has advised shareholders to independently evaluate the offer against market performance and their investment goals.

Peer Comparison

Bliss GVS Pharma operates within the broader pharmaceutical industry. Anupam Rasayan is in the specialty chemicals sector. A direct peer comparison for this specific transaction is less relevant than assessing the valuation discrepancy against industry norms for change-of-control transactions.

Context Metrics (Time-Bound)

• Offer Price: INR 299.00 per share.
• Offer Size: 2,77,26,848 shares (26% of expanded voting share capital).
• Total Consideration: ₹829.03 crore.
• Acquisition Trigger: 4,58,03,024 shares (43.11% equity).
• Market Price (BSE): INR 482.50 (July 17, 2026).
• Market Price (NSE): INR 483.50 (July 17, 2026).

What to Track Next

Investors will be closely watching the response to the open offer. The success rate will indicate shareholder sentiment towards the offer price versus the market price. Future integration plans and operational synergies between Anupam Rasayan and Bliss GVS Pharma will also be key.